Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

15.6%

5 terminated/withdrawn out of 32 trials

Success Rate

82.1%

-4.4% vs industry average

Late-Stage Pipeline

9%

3 trials in Phase 3/4

Results Transparency

30%

7 of 23 completed trials have results

Key Signals

2 recruiting7 with results4 withdrawn

Enrollment Performance

Analytics

Phase 1
20(64.5%)
Phase 2
8(25.8%)
Phase 3
3(9.7%)
31Total
Phase 1(20)
Phase 2(8)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (32)

Showing 20 of 32 trials
NCT07036133Phase 1Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

Role: lead

NCT06072131Phase 3Recruiting

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Role: lead

NCT02680795Phase 1Completed

Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

Role: lead

NCT05170334Phase 2Active Not Recruiting

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Role: collaborator

NCT04703920Phase 1Completed

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Role: collaborator

NCT05608343Phase 3Completed

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

Role: lead

NCT05571943Phase 3Completed

A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

Role: lead

NCT04184869Phase 1Completed

Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials

Role: lead

NCT04448834Phase 2Withdrawn

Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL

Role: collaborator

NCT02594267Phase 1Completed

A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

Role: lead

NCT04315155Phase 1Withdrawn

Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation

Role: collaborator

NCT01660633Phase 2Completed

Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

Role: lead

NCT04243434Phase 1Unknown

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Role: lead

NCT01789723Phase 1Withdrawn

Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

Role: lead

NCT01820091Phase 1Withdrawn

Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

Role: lead

NCT01222780Phase 1Completed

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

Role: lead

NCT01110733Completed

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Role: lead

NCT00481871Phase 1Completed

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Role: lead

NCT01118624Phase 2Completed

Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer

Role: lead

NCT01310244Phase 1Completed

MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC

Role: lead